(Total Views: 348)
Posted On: 04/13/2019 2:53:54 PM
Post# of 154975
Yes, that paper took a survey to estimate high vs low expression. They got 29% for high--if you take your 13% intermediate + 12% strong, that matches fairy close. I would say around the estimate is probably 1/4 to 1/3, 25% to 33%. Though if I was in the 29% group with weak ccr5 expression, I would personally be requesting leronlimab.
If you look at it another way, of the people in the study, 9 out of 31 died within 5 years with low expression and 9 out of 10 died with high expression. So leronlimab could possibly cut CRC 5 year patients deaths by half, from 18 to 9, though if I had to guess, I would say leronlimab would reduce the deaths in the high expression group from 10% to 70% (matching the low expression group), i.e 18 total down to 12 total or down 33% (instead of the possible 50%).
If you look at it another way, of the people in the study, 9 out of 31 died within 5 years with low expression and 9 out of 10 died with high expression. So leronlimab could possibly cut CRC 5 year patients deaths by half, from 18 to 9, though if I had to guess, I would say leronlimab would reduce the deaths in the high expression group from 10% to 70% (matching the low expression group), i.e 18 total down to 12 total or down 33% (instead of the possible 50%).
Quote:
To evaluate the clinical relevance of the abovementioned results, we examined CCR5 expression in CRC cells with 89 clinical specimens by immunohistochemical analysis. We found that 20 cases (20/89; 29%) had high levels of CCR5, whereas 69 cases (69/89; 71%) had comparatively lower levels (Fig. 4a)
(0)
(0)
